UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

Annals of surgical oncology, 2013-08, Vol.20 (8), p.2787-2795

2013

Volltextzugriff (PDF)

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Annals of surgical oncology, 2009-04, Vol.16 (4), p.836-847, Article 836

2009

Volltextzugriff (PDF)

Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore

PloS one, 2014-12, Vol.9 (12), p.e114310-e114310

2014

Volltextzugriff (PDF)

Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases

Annals of surgical oncology, 2018-06, Vol.25 (6), p.1709-1715

2018

Volltextzugriff (PDF)

What Defines the Value of Minimally Invasive Surgery for Cancer Patients?

Annals of surgical oncology, 2024-04, Vol.31 (4), p.2204-2207

2024

Volltextzugriff (PDF)

Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer

Annals of surgical oncology, 2015-07, Vol.22 (7), p.2416-2423

2015

Volltextzugriff (PDF)

Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C

Annals of surgical oncology, 2009-08, Vol.16 (8), p.2181-2187

2009

Volltextzugriff (PDF)

Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer

Annals of surgical oncology, 2015-04, Vol.22 (4), p.1168-1175

2015

Volltextzugriff (PDF)

Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study

Annals of surgical oncology, 2024-03, Vol.31 (3), p.1919-1932

2024

Volltextzugriff (PDF)

Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival

Journal of gastrointestinal surgery, 2014, Vol.18 (1), p.16-25

2014

Volltextzugriff (PDF)

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience

Journal of gastrointestinal surgery, 2017, Vol.21 (1), p.164-174

2017

Volltextzugriff (PDF)

Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6

Annals of surgical oncology, 2024, Vol.31 (1), p.6-9

2024

Volltextzugriff (PDF)

ASO Visual Abstract: Standardization of Colon Resection for Cancer—An Overview of the American College of Surgeons Commission on Cancer Standard 5.6

Annals of surgical oncology, 2024, Vol.31 (1), p.72-73

2024

Volltextzugriff (PDF)

ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9

Annals of surgical oncology, 2024-03, Vol.31 (3), p.1842-1843

2024

Volltextzugriff (PDF)

ASO Visual Abstract: Serum CEA as Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment—A TAPS Consortium Study

Annals of surgical oncology, 2024-03, Vol.31 (3), p.1954-1955

2024

Volltextzugriff (PDF)

Detection and Management of Perioperative Hyperglycemia at a Tertiary Cancer Center

Annals of surgical oncology, 2024-05, Vol.31 (5), p.3017-3023

2024

Volltextzugriff (PDF)

Transmesocolic Approach for Robotic Duodenal Operations

Annals of surgical oncology, 2023-05, Vol.30 (5), p.2959-2959

2023

Volltextzugriff (PDF)

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

Annals of surgical oncology, 2011-03, Vol.18 (3), p.608-610

2011

Volltextzugriff (PDF)

Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Journal of gastrointestinal surgery, 2015-01, Vol.19 (1), p.80-87

2015

Volltextzugriff (PDF)

Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy

Annals of surgical oncology, 2015-10, Vol.22 (11), p.3522-3529

2015

Volltextzugriff (PDF)

Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma

Annals of surgical oncology, 2023-10, Vol.30 (11), p.6662-6670

2023

Volltextzugriff (PDF)

Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas

Journal of gastrointestinal surgery, 2016-12, Vol.20 (12), p.1966-1974

2016

Volltextzugriff (PDF)

Resection of At-Risk Mesenteric Lymph Nodes Is Associated with Improved Survival in Patients with Small Bowel Neuroendocrine Tumors

World journal of surgery, 2013-07, Vol.37 (7), p.1695-1700

2013

Volltextzugriff (PDF)

Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer

Journal of gastrointestinal surgery, 2023-02, Vol.27 (2), p.319-327

2023

Volltextzugriff (PDF)

Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer

Journal of gastrointestinal surgery, 2014-02, Vol.18 (2), p.269-278

2014

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

ThemaMedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(81)

Sprache

Englisch
(81)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore

Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases

What Defines the Value of Minimally Invasive Surgery for Cancer Patients?

Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer

Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C

Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer

Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study

Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience

Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6

ASO Visual Abstract: Standardization of Colon Resection for Cancer—An Overview of the American College of Surgeons Commission on Cancer Standard 5.6

ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9

ASO Visual Abstract: Serum CEA as Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment—A TAPS Consortium Study

Detection and Management of Perioperative Hyperglycemia at a Tertiary Cancer Center

Transmesocolic Approach for Robotic Duodenal Operations

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy

Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma

Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas

Resection of At-Risk Mesenteric Lymph Nodes Is Associated with Improved Survival in Patients with Small Bowel Neuroendocrine Tumors

Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer

Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer

Aktive Filter

Suchergebnisse filtern